InvestorsHub Logo
Followers 24
Posts 501
Boards Moderated 1
Alias Born 03/09/2014

Re: None

Monday, 08/03/2020 10:54:48 AM

Monday, August 03, 2020 10:54:48 AM

Post# of 1047
EIGR ”Although no synthetic IFN-lambda is yet FDA-approved, preliminary results in a clinical trial in hepatitis D patients show that it has the same antiviral potency as type I IFN but is much safer and better tolerated. A study in mice found that synthetic IFN-lambda was as effective as IFN-alpha in treating influenza but didn’t have the same proinflammatory effects.”
https://www.frontiersin.org/articles/10.3389/fneur.2020.00146/full